Raymond James & Associates Incyte Corp Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Incyte Corp stock. As of the latest transaction made, Raymond James & Associates holds 3,938 shares of INCY stock, worth $232,420. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,938
Previous 36,484
89.21%
Holding current value
$232,420
Previous $2.29 Million
90.22%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding INCY
# of Institutions
617Shares Held
215MCall Options Held
366KPut Options Held
445K-
Baker Bros. Advisors LP New York, NY36.2MShares$2.14 Billion26.1% of portfolio
-
Black Rock Inc. New York, NY23.2MShares$1.37 Billion0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA22.7MShares$1.34 Billion0.03% of portfolio
-
Dodge & Cox San Francisco, CA15.4MShares$910 Million0.54% of portfolio
-
State Street Corp Boston, MA9.9MShares$584 Million0.03% of portfolio
About INCYTE CORP
- Ticker INCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 222,431,008
- Market Cap $13.1B
- Description
- Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...